Exelixis | EXEL - Creditori Commerciali





Creditori Commerciali Cambiamento Data
Acadia Pharmaceuticals USD 44.57M 32.32M 2026-06
Agios Pharmaceuticals USD 16.34M 2.6M 2026-06
Akebia Therapeutics USD 9.42M 1.04M 2026-06
Amgen USD 2.86B 16.65B 2026-06
AstraZeneca USD 22.89B 388M 2026-06
Bayer EUR 6.39B 192M 2026-06
BioMarin Pharmaceutical USD 913.67M 120.52M 2026-06
Bristol-Myers Squibb USD 4.16B 76M 2026-06
Cytokinetics USD 20.51M 4.2M 2026-06
Eisai JPY 87.53B 11.64B 2026-06
Eli Lilly USD 6.11B 1.08B 2026-06
Exelixis USD 39.06M 14.91M 2026-06
Genmab DKK 116M 110M 2026-06
Glaxosmithkline GBP 14.34B 6.39B 2026-03
Incyte USD 1.39B 1.16B 2026-06
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
MacroGenics USD 3.44M 845K 2026-06
Merck USD 3.83B 36M 2026-06
Moderna USD 167M 6M 2026-06
Nektar Therapeutics USD 10.03M 744K 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novartis USD 4.26B 64M 2026-06
Pfizer USD 4.58B 75M 2026-06
Puma Biotechnology USD 6.39M 962K 2025-09
Sanofi EUR 22.71B 219M 2026-03
Takeda JPY 446.78B 44.56B 2026-06
Ultragenyx Pharmaceutical USD 39M 3M 2026-06
Xencor USD 12.65M 4.73M 2026-06